Pulse Biosciences, Inc. PLSE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pulse Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pulse Biosciences, Inc.'s additional paid-in capital?
- Pulse Biosciences, Inc. (PLSE) reported additional paid-in capital of $548.09M in Q1 2026.
- How has Pulse Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- Pulse Biosciences, Inc.'s additional paid-in capital increased by 4.3% year-over-year, from $525.68M to $548.09M.
- What is the long-term trend for Pulse Biosciences, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Pulse Biosciences, Inc.'s additional paid-in capital has grown at a 22.7% compound annual growth rate (CAGR), from $195.41M to $543.87M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.